QQQ   303.46 (+1.28%)
AAPL   122.72 (+3.08%)
MSFT   216.21 (+1.00%)
FB   286.55 (+3.46%)
GOOGL   1,795.36 (+2.33%)
AMZN   3,220.08 (+1.64%)
TSLA   584.76 (+3.02%)
NVDA   535.60 (-0.09%)
BABA   264.01 (+0.25%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.63 (-0.03%)
T   28.87 (+0.42%)
NIO   45.36 (-10.23%)
F   9.24 (+1.76%)
ACB   9.75 (-16.52%)
NFLX   504.58 (+2.83%)
BA   213.01 (+1.09%)
GILD   61.12 (+0.74%)
DIS   149.44 (+0.97%)
QQQ   303.46 (+1.28%)
AAPL   122.72 (+3.08%)
MSFT   216.21 (+1.00%)
FB   286.55 (+3.46%)
GOOGL   1,795.36 (+2.33%)
AMZN   3,220.08 (+1.64%)
TSLA   584.76 (+3.02%)
NVDA   535.60 (-0.09%)
BABA   264.01 (+0.25%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.63 (-0.03%)
T   28.87 (+0.42%)
NIO   45.36 (-10.23%)
F   9.24 (+1.76%)
ACB   9.75 (-16.52%)
NFLX   504.58 (+2.83%)
BA   213.01 (+1.09%)
GILD   61.12 (+0.74%)
DIS   149.44 (+0.97%)
QQQ   303.46 (+1.28%)
AAPL   122.72 (+3.08%)
MSFT   216.21 (+1.00%)
FB   286.55 (+3.46%)
GOOGL   1,795.36 (+2.33%)
AMZN   3,220.08 (+1.64%)
TSLA   584.76 (+3.02%)
NVDA   535.60 (-0.09%)
BABA   264.01 (+0.25%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.63 (-0.03%)
T   28.87 (+0.42%)
NIO   45.36 (-10.23%)
F   9.24 (+1.76%)
ACB   9.75 (-16.52%)
NFLX   504.58 (+2.83%)
BA   213.01 (+1.09%)
GILD   61.12 (+0.74%)
DIS   149.44 (+0.97%)
QQQ   303.46 (+1.28%)
AAPL   122.72 (+3.08%)
MSFT   216.21 (+1.00%)
FB   286.55 (+3.46%)
GOOGL   1,795.36 (+2.33%)
AMZN   3,220.08 (+1.64%)
TSLA   584.76 (+3.02%)
NVDA   535.60 (-0.09%)
BABA   264.01 (+0.25%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.63 (-0.03%)
T   28.87 (+0.42%)
NIO   45.36 (-10.23%)
F   9.24 (+1.76%)
ACB   9.75 (-16.52%)
NFLX   504.58 (+2.83%)
BA   213.01 (+1.09%)
GILD   61.12 (+0.74%)
DIS   149.44 (+0.97%)
Log in
NASDAQ:AQST

Aquestive Therapeutics Stock Forecast, Price & News

$6.89
-0.17 (-2.41 %)
(As of 12/1/2020 12:00 AM ET)
Add
Compare
Today's Range
$6.77
Now: $6.89
$7.12
50-Day Range
$4.71
MA: $5.78
$7.21
52-Week Range
$1.41
Now: $6.89
$10.00
Volume712,076 shs
Average Volume890,423 shs
Market Capitalization$231.64 million
P/E RatioN/A
Dividend YieldN/A
Beta3.81
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of epileptic seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The company's proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly. It also develops APL-130277, a sublingual film formulation of apomorphine to treat Parkinson's disease. Aquestive Therapeutics, Inc. was founded in 2004 and is headquartered in Warren, New Jersey.
Aquestive Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.86 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AQST
CUSIPN/A
CIKN/A
Phone908-941-1900
Employees232

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$52.61 million
Book Value($1.09) per share

Profitability

Net Income$-66,250,000.00

Miscellaneous

Market Cap$231.64 million
Next Earnings Date3/10/2021 (Estimated)
OptionableNot Optionable
$6.89
-0.17 (-2.41 %)
(As of 12/1/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AQST News and Ratings via Email

Sign-up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aquestive Therapeutics (NASDAQ:AQST) Frequently Asked Questions

How has Aquestive Therapeutics' stock price been impacted by Coronavirus?

Aquestive Therapeutics' stock was trading at $2.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AQST stock has increased by 134.4% and is now trading at $6.89.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Aquestive Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aquestive Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Aquestive Therapeutics?

Wall Street analysts have given Aquestive Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aquestive Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Aquestive Therapeutics' next earnings date?

Aquestive Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021.
View our earnings forecast for Aquestive Therapeutics
.

How were Aquestive Therapeutics' earnings last quarter?

Aquestive Therapeutics, Inc. (NASDAQ:AQST) issued its earnings results on Monday, November, 9th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.46) by $0.03.
View Aquestive Therapeutics' earnings history
.

What guidance has Aquestive Therapeutics issued on next quarter's earnings?

Aquestive Therapeutics updated its FY 2020 After-Hours earnings guidance on Wednesday, November, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $42-46 million, compared to the consensus revenue estimate of $47.32 million.

What price target have analysts set for AQST?

6 equities research analysts have issued 12 month price targets for Aquestive Therapeutics' stock. Their forecasts range from $7.00 to $33.00. On average, they expect Aquestive Therapeutics' share price to reach $15.67 in the next twelve months. This suggests a possible upside of 127.4% from the stock's current price.
View analysts' price targets for Aquestive Therapeutics
.

Who are some of Aquestive Therapeutics' key competitors?

What other stocks do shareholders of Aquestive Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aquestive Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), Bionano Genomics (BNGO), OrganiGram (OGI), Novan (NOVN), Outlook Therapeutics (OTLK) and KushCo (KSHB).

Who are Aquestive Therapeutics' key executives?

Aquestive Therapeutics' management team includes the following people:
  • Mr. Keith J. Kendall, CEO, Pres & Director (Age 62, Pay $859.98k)
  • Mr. John T. Maxwell, Sr. VP & CFO (Age 55, Pay $537.15k)
  • Mr. Daniel Barber, Sr. VP & COO (Age 44, Pay $639.97k)
  • Mr. Alexander Mark Schobel, Chief Innovation & Technology Officer (Age 61)
  • Ms. Lori J. Braender Esq., Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 64)
  • Mr. Lauren Walrath, Head of Corp. Marketing & Communications
  • Ms. Theresa Wood, Sr. VP of HR & Organizational Devel. (Age 57)
  • Dr. Eric Dadey Ph.D., Sr. Vice-Pres of R&D
  • Mr. Peter E. Boyd, Sr. VP of Bus. Process & Information Technology (Age 54)
  • Mr. Kenneth W. Marshall, Sr. VP & Chief Commercial Officer (Age 61)

When did Aquestive Therapeutics IPO?

(AQST) raised $60 million in an initial public offering on Wednesday, July 25th 2018. The company issued 4,000,000 shares at $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers.

What is Aquestive Therapeutics' stock symbol?

Aquestive Therapeutics trades on the NASDAQ under the ticker symbol "AQST."

Who are Aquestive Therapeutics' major shareholders?

Aquestive Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.78%), Morgan Stanley (1.91%), Charles Schwab Investment Management Inc. (0.54%), Wedbush Securities Inc. (0.31%), Oak Grove Capital LLC (0.26%) and Wells Fargo & Company MN (0.19%). Company insiders that own Aquestive Therapeutics stock include Alexander Mark Schobel, Daniel Barber, James S Scibetta, John T Maxwell, Keith J Kendall, Lori J Braender, Peter E Boyd and Theresa Wood.
View institutional ownership trends for Aquestive Therapeutics
.

Which major investors are selling Aquestive Therapeutics stock?

AQST stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Wedbush Securities Inc., and New York State Common Retirement Fund. Company insiders that have sold Aquestive Therapeutics company stock in the last year include Alexander Mark Schobel, John T Maxwell, and Keith J Kendall.
View insider buying and selling activity for Aquestive Therapeutics
.

Which major investors are buying Aquestive Therapeutics stock?

AQST stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Charles Schwab Investment Management Inc., Massachusetts Financial Services Co. MA, Jane Street Group LLC, Cubist Systematic Strategies LLC, Dupont Capital Management Corp, ExodusPoint Capital Management LP, and California Public Employees Retirement System. Company insiders that have bought Aquestive Therapeutics stock in the last two years include Alexander Mark Schobel, Daniel Barber, James S Scibetta, John T Maxwell, Keith J Kendall, Lori J Braender, Peter E Boyd, and Theresa Wood.
View insider buying and selling activity for Aquestive Therapeutics
.

How do I buy shares of Aquestive Therapeutics?

Shares of AQST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aquestive Therapeutics' stock price today?

One share of AQST stock can currently be purchased for approximately $6.89.

How big of a company is Aquestive Therapeutics?

Aquestive Therapeutics has a market capitalization of $231.64 million and generates $52.61 million in revenue each year. The company earns $-66,250,000.00 in net income (profit) each year or ($2.42) on an earnings per share basis. Aquestive Therapeutics employs 232 workers across the globe.

What is Aquestive Therapeutics' official website?

The official website for Aquestive Therapeutics is www.aquestive.com.

How can I contact Aquestive Therapeutics?

Aquestive Therapeutics' mailing address is 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. The company can be reached via phone at 908-941-1900 or via email at [email protected]

This page was last updated on 12/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.